ENSC · Ensysce Biosciences, Inc.
$0.44
+0.05 (+13.35%)
At close · Sep 2
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These matters, among others, raise substantial doubt about the Company's ability to continue as a going concern. While the Company believes in the viability of its strategy to ultimately realize revenues and in its ability to raise additional funds, management cannot be certain that additional funding will be available on acceptable terms, or at all. The Company's ability to continue as a going concern is dependent upon its ability to obtain adequate financing and achieve profitable operations. As a result, these plans do not alleviate substantial doubt about the Company's ability to continue as a going concern for a period of 12 months following the date these consolidated financial statements were issued.”View the 10-Q filed Aug 13, 2026
Market Cap
$7.45M
Shares
19.46M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.39
Open$0.39
Day$0.38–0.39
52W close$0.25–2.57
Avg vol 30d29.1M
Short int1.1M · 5.9% float · 1.0d
Short vol31%
Last earningsAug 18, 2026
DataDec 2024–Sep 2026
Filing10-Q · Aug 13
Raw chart and full-history price indicators begin at the captured split on Dec 6, 2024; bars on opposite sides are not compared.
Up next
Next earnings call
Jun 5, 2027
Est · unconfirmed
· in 39 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$4.50M
Trailing 12 months
Net income (TTM)
−$12.62M
Trailing 12 months
Revenue growth YoY
-15.1%
Year over year
Operating margin
-281.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$676,704
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+491.9%
Year over year · more shares
Price change (1Y)
-81.4%
Trailing year
Short interest
5.9%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−38%
below
Price vs 50-day avg
+18%
above
RSI (14)
53
neutral
MACD trend
Negative
52-week position
6%
near low
Momentum
relative strength
1-month return
+1%
trailing
6-month return
−15%
trailing
YTD return
−58%
this year
Relative strength
−28%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+20% holders QoQ · +5 funds added
Insider flow
Accumulating
Net +$198.0K over 90 days · 0% sells
Short interest
Rising
5.86% of float · ▲ +496.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
18 holders — near 3-yr high, broad support
Squeeze score
64
elevated · 0–100
Fundamentals
Revenue growth
−3%
Y/Y
EPS growth
+65%
Y/Y
Free cash flow
$-7.9M
Quant / Vol
risk profile
Volatility
133%
annualized · 1-yr
Max drawdown
−90%
past year
ATR
13.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−38%
Bearish
Price vs 50-day avg
+18%
Bullish
RSI (14)
53
Neutral
MACD trend
Negative
Bearish
52-week position
6%
Bearish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+20% holders QoQ · +5 funds added
Insider flow
Accumulating
Net +$198.0K over 90 days · 0% sells
Short interest
Rising
5.86% of float · ▲ +496.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
18 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $0
Now $0 · 6%
Range high $3
vs 200-day avg -38%
vs 50-day avg +18%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ENSC
this stock
Ensysce Biosciences, Inc.
|
$7.45M | -57.8% | -2.8% | — | 5.9% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$140.51B | +20.8% | +46.2% | 32.3 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$84.82B | +6.7% | +20.8% | 20.4 | 2.3% |
|
ARGX
Argenx SE
|
$64.16B | +22.3% | — | — | 1.9% |
|
MRNA
Moderna, Inc.
|
$61.59B | +423.1% | +4.3% | — | 13.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
Raw-price comparisons begin at the captured split on Dec 6, 2024; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ENSC | -3.7% | +1.1% | -15.3% | -1.2% | -57.8% |
| SPY | -0.5% | -1.2% | +12.6% | -0.7% | +11.7% |
| vs SPY | -3.2% | +2.3% | -27.9% | -0.5% | -69.5% |
Key facts
CIK
1716947
CUSIP
293602504
13F (30d)
17 filings
17 filers
Visit website
Investor relations